KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program.

Details

Serval ID
serval:BIB_C9BB6B74850A
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program.
Journal
Virchows Archiv
Author(s)
van Krieken J.H., Jung A., Kirchner T., Carneiro F., Seruca R., Bosman F.T., Quirke P., Fléjou J.F., Plato Hansen T., de Hertogh G., Jares P., Langner C., Hoefler G., Ligtenberg M., Tiniakos D., Tejpar S., Bevilacqua G., Ensari A.
ISSN
0945-6317 (Print)
ISSN-L
0945-6317
Publication state
Published
Issued date
2008
Peer-reviewed
Oui
Volume
453
Number
5
Pages
417-431
Language
english
Notes
Publication types: Journal Article ; Review Publication Status: ppublish
Abstract
Novel therapeutic agents targeting the epidermal growth factor receptor (EGFR) have improved outcomes for patients with colorectal carcinoma. However, these therapies are effective only in a subset of patients. Activating mutations in the KRAS gene are found in 30-40% of colorectal tumors and are associated with poor response to anti-EGFR therapies. Thus, KRAS mutation status can predict which patient may or may not benefit from anti-EGFR therapy. Although many diagnostic tools have been developed for KRAS mutation analysis, validated methods and standardized testing procedures are lacking. This poses a challenge for the optimal use of anti-EGFR therapies in the management of colorectal carcinoma. Here we review the molecular basis of EGFR-targeted therapies and the resistance to treatment conferred by KRAS mutations. We also present guideline recommendations and a proposal for a European quality assurance program to help ensure accuracy and proficiency in KRAS mutation testing across the European Union.
Keywords
Antibodies/therapeutic use, Colorectal Neoplasms/drug therapy, Colorectal Neoplasms/genetics, Europe, Genetic Testing, Humans, Point Mutation/genetics, Predictive Value of Tests, Proto-Oncogene Proteins/genetics, Quality Assurance, Health Care, Receptor, Epidermal Growth Factor/antagonists & inhibitors, Receptor, Epidermal Growth Factor/immunology, ras Proteins/genetics
Pubmed
Web of science
Open Access
Yes
Create date
20/05/2009 19:11
Last modification date
20/08/2019 15:44
Usage data